• Xiaoli Liao, Junbao Wei, Yongqiang Li, Jianhong Zhong, Zhihui Liu, Sina Liao, Qian Li, and Changyuan Wei.
• Department of First Chemotherapy Department of Therapeutic Radiology Hepatobiliary Surgery Department Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
• Medicine (Baltimore). 2018 Aug 1; 97 (34): e11970e11970.

AbstractThe aim of the present study was to meta-analyze the literature on the diagnostic value of 18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) with or without computed tomography (CT) in detecting extrahepatic metastases or local residual/recurrent hepatocellular carcinoma (HCC).Systematic review of literature in MEDLINE, Embase, and Cochrane databases was conducted in March 2017, and relevant studies analyzing the diagnostic performance of F-FDG PET with or without CT were meta-analyzed.Meta-analysis was carried out on data from 11 studies involving 572 patients. F-FDG PET, with or without CT, showed pooled sensitivity of 64% and pooled specificity of 95%. Pooled sensitivity was similar with CT (74%) or without (52%; P = .279). Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481).F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC. Adding CT to F-FDG PET may improve diagnostic performance, but the available evidence suggests that the improvement is not statistically significant.

23 keywords...

hide…